Tabula Rasa HealthCare Reports Third Quarter 2022 Results

Rhea-AI Summary

Tabula Rasa HealthCare (NASDAQ: TRHC) reported Q3 2022 results showing a 14% revenue increase year-over-year to $77.1 million. However, the company experienced a GAAP net loss of $25.9 million, compared to $11.8 million the previous year, largely due to costs associated with leadership changes. Adjusted EBITDA decreased to $2.1 million from $3.1 million. The company holds $80.8 million in cash as of September 30, 2022. PACE participants increased by 8%, bolstering future growth outlook amidst robust demand.

Positive

• Revenue from continuing operations increased 14% to $77.1 million.
• Cash increased to $80.8 million as of September 30, 2022, up from $26.5 million.
• PACE participants grew by 8%, indicating strong demand.
• The company is positioned to expand into larger value-based care markets.

Negative

• GAAP net loss from continuing operations increased to $25.9 million from $11.8 million.
• Adjusted EBITDA decreased to $2.1 million from $3.1 million.
• Service revenue decreased by 2% compared to the prior year.

• Revenue from continuing operations of $77.1 million increased 14% vs. a year ago
• GAAP net loss from continuing operations of $25.9 million vs. $11.8 million a year ago
• Adjusted EBITDA from continuing operations of $2.1 million vs. $3.1 million a year ago
• Cash of $80.8 million as of September 30, 2022, vs. $26.5 million as of June 30, 2022

MOORESTOWN, N.J., Nov. 3, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (Nasdaq:TRHC), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the third quarter ended September 30, 2022.

"We delivered another quarter of solid revenue growth and continue on a pace to perform strongly against our 2022 guidance. With our strong position in PACE today, serving more than eight out of every ten participants, we have a robust foundation to build upon as we enter adjacent value-based care markets that are exponentially larger and focus on high-cost, high-risk patients. We are committed to driving shareholder value by narrowing our focus to core assets and markets with a competitive advantage to improve top-line growth and enhance margins," said Brian Adams, President and Interim CEO.

Key Financial Results
(in millions except percentages)
		Three Months Ended September 30,						Year over Year				Q3 2022
		2022			2021			Change				Guidance
Revenue from continuing operations		$	77.1		$	67.9		14	%		$	72.5 – 75.0
Net loss from continuing operations		$	(25.9)		$	(11.8)		(120)	%
Adjusted EBITDA from continuing operations		$	2.1		$	3.1		(35)	%

Third Quarter 2022 Financial Results

All comparisons, unless otherwise noted, are to the three months ended September 30, 2021, and reflect continuing operations.

• Revenue – Revenue of $77.1 million increased 14% compared to $67.9 million in 2021. Product (medication) revenue of $59.8 million increased 19% due to strong PACE participant growth. Service revenue of $17.3 million decreased 2% from the year ago period. Excluding $2.3 million of revenue related to the concluded CMS Enhanced Medication Therapy Management ("EMTM") pilot program included in the third quarter of 2021, service revenue increased 13%, led by growth in our pharmacy benefit management ("PBM") and risk adjustment services, each of which grew by more than 20%.
  
  
• GAAP net loss – GAAP net loss from continuing operations of $25.9 million compared to a loss of $11.8 million a year ago with the decline largely driven by costs, including stock-based compensation of $8.1 million and other expenses, related to the leadership transition and cooperation agreement with Indaba Capital Management announced on September 14, 2022. Gross margin, excluding depreciation and amortization, of $16.9 million (21.9% of revenue) increased as compared to $16.7 million (24.6% of revenue) a year ago. The decline in gross margin as a percentage of revenue was largely driven by product and service revenue mix, as well as increased shipping charges.
  
  GAAP net loss from discontinued operations of $14.2 million compares to a loss of $5.4 million a year ago and includes the SinfoníaRx and DoseMe businesses, as well as one month of the PrescribeWellness business. As previously announced, TRHC's sale of PrescribeWellness closed on August 1, 2022.

• Adjusted EBITDA – Adjusted EBITDA from continuing operations of $2.1 million (2.7% margin) declined as compared to $3.1 million (4.6% margin) a year ago, primarily due to the timing of cash compensation expense, as well as the reasons noted above negatively impacting gross margin.

A reconciliation of generally accepted accounting principles ("GAAP") in the United States to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."

Operational Metrics

To provide greater transparency into our financial results, we are providing the following operational metrics.

• Total PACE participants utilizing at least one of our solutions increased by 8% as of September 30, 2022, to 52,230, as compared to September 30, 2021.
• Average PACE per member per month revenue increased 9% during the third quarter of 2022, as compared to the same period a year ago. This metric is defined as quarterly revenue for PACE clients across all service lines divided by quarterly member months.
• PACE participants for our pharmacy services as of September 30, 2022, increased 18% as compared to a year ago. This growth was driven by continued participant growth at existing PACE centers and the onboarding of a large PACE program in California completed during the third quarter.
• PACE backlog as of September 30, 2022, stands at 56 implementations (by product and service), valued at $54 million in annual revenue at maturity, which the Company defines as enrollment of 250 participants. By comparison, these figures were 65 implementations and $59 million as of June 30, 2022.
• PACE implementations during the third quarter and first nine months of 2022 totaled 16 and 38, respectively, as compared with 4 and 19, respectively, in the same period a year ago.

Business Outlook

This outlook updates the previously issued financial guidance that was provided on August 4, 2022.

									Year over year growth
		Low			High				Low		High
Three Months Ended December 31, 2022		(in millions except percentages)
CareVention HealthCare revenue		$	76.5		$	79.0			16 %		20 %
Other revenue from continuing operations		$	1.0		$	1.5			NM		NM
Total revenue from continuing operations		$	77.5		$	80.5			12 %		17 %
									Year over year growth
		Low			High				Low		High
Year Ended December 31, 2022*		(in millions except percentages)
CareVention HealthCare revenue		$	290.5		$	293.0			17 %		18 %
Other revenue from continuing operations		$	3.5		$	4.0			NM		NM
Total revenue from continuing operations		$	294.0		$	297.0			13 %		14 %

*Totals may not add due to rounding

NM = not meaningful

Upcoming Events

Members of TRHC's executive team will be presenting at the following conferences:

• Piper Sandler's 34^th Annual Healthcare Conference from November 29^th to December 1^st, and
• The Benchmark Company 11^th Annual Discovery One-on-One Conference on December 1^st.

Quarterly Conference Call

The third quarter 2022 earnings conference call and webcast will be held tomorrow, Friday, November 4, 2022, at 8:30 a.m. ET. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to receive the dial-in number along with a unique PIN number that is required to access the call. A replay of the earnings call will be available via webcast at the Investor Relations section of TRHC's website (ir.tabularasahealthcare.com).

About Tabula Rasa HealthCare

Tabula Rasa HealthCare provides medication safety solutions that empower healthcare professionals and consumers to optimize medication regimens, combating medication overload and reducing adverse drug events – the fourth leading cause of death in the U.S. TRHC's proprietary technology solutions, including MedWise®, improve patient outcomes, reduce hospitalizations, and lower healthcare costs. TRHC's extensive clinical tele-pharmacy network improves care for patients nationwide. Its solutions are trusted by health plans and pharmacies to help drive value-based care. For more information, visit TRHC.com.

Non-GAAP Financial Measures

In addition to reporting all financial information required in accordance with GAAP, TRHC is also reporting Adjusted EBITDA, which is considered a non-GAAP financial measure. Generally, a non-GAAP financial measure is a numerical measure of a company's performance or financial position that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. Adjusted EBITDA consists of net loss plus certain other expenses, which include interest expense, provision for income tax, depreciation and amortization, impairment charges, business optimization expenses, severance costs, executive transition costs, cooperation agreement costs, divestiture-related expense, acquisition-related expense, stock-based compensation expense, loss on disposal of business, and settlement costs. TRHC considers business optimization expenses to include contract termination payments, severance, retention payments, and other employee and non-recurring vendor costs incurred related to our business optimization initiatives during 2022. TRHC considers executive transition costs to include nonrecurring costs related to the hiring and onboarding of new named executive officers and separation costs related to former named executive officers. TRHC considers cooperation agreement costs to include legal, professional services, and other non-recurring costs related to the Company's cooperation agreement with Indaba Capital Management. TRHC considers severance costs to include severance payments related to the realignment of our resources. TRHC considers divestiture-related expense to include nonrecurring direct transaction costs. TRHC considers acquisition-related expense to include nonrecurring direct transaction and integration costs. TRHC considers loss on disposal of business to include the nonrecurring loss resulting from the sale of the PrescribeWellness business. TRHC considers settlement costs to include amounts payable by TRHC or reductions to amounts owed to TRHC as a result of a contractual settlement. 

TRHC presents this non-GAAP financial measure in this release because it considers it to be an important supplemental measure of performance. TRHC uses this non-GAAP financial measure for planning purposes, including analysis of the Company's performance against prior periods, the preparation of operating budgets and determination of appropriate levels of operating and capital investments. TRHC believes that this non-GAAP financial measure provides additional insight for analysts and investors in evaluating the Company's financial and operational performance. TRHC also intends to provide this non-GAAP financial measure as part of the Company's future earnings discussions and, therefore, its inclusion should provide consistency in the Company's financial reporting.

Non-GAAP financial measures have limitations as an analytical tool. Investors are encouraged to review the reconciliation of Adjusted EBITDA to its most directly comparable GAAP measures provided in this release, including in the accompanying tables.

Safe Harbor Statement

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words such as "believe," "will," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "could," "potentially" or the negative of these terms or similar expressions. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other "forward-looking" information. These statements relate to, without limitation, our future plans, objectives, expectations, intentions, the potential sales of the SinfoníaRx and DoseMe businesses of the Company and the timing and benefits thereof, and financial performance and the assumptions that underlie these statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to: (i) the overall macroeconomic environment, including the effects of inflation, supply chain constraints, and the impact of changes in interest rates, on our business and results of operations; (ii) our ability to adapt to changes or trends within the market for healthcare in the U.S.; (iii) a significant increase in competition from a variety of companies in the healthcare industry; (iv) developments and changes in laws and regulations, including increased regulation of the healthcare industry through legislative action and revised rules and standards; (v) the extent to which we are successful in gaining new long-term relationships with clients or retaining existing clients; (vi) clients demands for our services and our ability to fulfill client demands; (vii) the growth and success of our clients, which is difficult to predict and is subject to factors outside of our control; (viii) our ability to maintain relationships with a specified drug wholesaler; (ix) increasing consolidation in the healthcare industry; (x) managing our growth effectively; (xi) fluctuations in operating results; (xii) our ability to manage our cash flows; (xiii) failure or disruption of our information technology and security systems; (xiv) dependence on or changes to our senior management and key employees; (xv) changes in our strategy as a result of our entry into the Cooperation Agreement with Indaba; (xvi) our future indebtedness and our ability to obtain additional financing, reduce expenses, or generate funds when necessary; (xvii) our ability to execute on our planned divestitures of our SinfoníaRx and DoseMe businesses, the costs associated therewith, and risks related to diverting management's attention from our ongoing business operations; (xviii) risks related to the volatility in our stock price; (xix) the impacts of the ongoing COVID-19 pandemic and other health epidemics; and (xx) the risks described in Part I, Item 1A of our 2021 Form 10-K and our other filings and reports filed with or furnished to the Securities and Exchange Commission. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments, except as required by applicable law. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.

 

UNAUDITED CONSOLIDATED BALANCE SHEETS (In thousands)
		September 30,			December 31,
		2022			2021
Assets
Current assets:
Cash		$	80,783		$	9,395
Restricted cash			7,389			6,038
Accounts receivable, net			18,960			21,405
Inventories			5,735			5,444
Prepaid expenses			3,484			3,812
Client claims receivable			16,193			11,257
Other current assets			20,439			18,033
Current assets of discontinued operations			26,861			14,511
Total current assets			179,844			89,895
Contingent consideration receivable			7,000			—
Property and equipment, net			10,038			11,778
Operating lease right-of-use assets			14,069			16,323
Software development costs, net			32,606			29,254
Goodwill			115,323			115,323
Intangible assets, net			40,275			45,358
Other assets			4,691			3,929
Noncurrent assets of discontinued operations			—			187,558
Total assets		$	403,846		$	499,418
Liabilities and stockholders' equity (deficit)
Current liabilities:
Current operating lease liabilities		$	3,195		$	3,275
Accounts payable			14,685			8,870
Client claims payable			9,537			8,398
Accrued expenses and other liabilities			59,507			40,997
Current liabilities of discontinued operations			11,132			12,380
Total current liabilities			98,056			73,920
Line of credit			—			29,500
Long-term debt, net of discount			231,868			319,299
Long-term debt – related party, net of discount			88,429			—
Noncurrent operating lease liabilities			13,223			15,792
Deferred income tax liability, net			889			1,402
Other long-term liabilities			3,032			176
Noncurrent liabilities of discontinued operations			—			3,573
Total liabilities			435,497			443,662
Stockholders' equity (deficit):
Common stock			3			3
Treasury stock			(3,350)			(4,292)
Additional paid-in capital			349,911			320,392
Accumulated deficit			(378,215)			(260,347)
Total stockholders' equity (deficit)			(31,651)			55,756
Total liabilities and stockholders' equity (deficit)		$	403,846		$	499,418

 

TABULA RASA HEALTHCARE, INC. UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts)
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2022			2021			2022			2021
Revenue:
Product revenue		$	59,780		$	50,321		$	166,645		$	139,021
Service revenue			17,321			17,589			50,163			51,964
Total revenue			77,101			67,910			216,808			190,985
Cost of revenue, exclusive of depreciation and amortization shown below:
Product cost			46,221			38,518			129,157			104,939
Service cost			14,014			12,697			40,430			37,875
Total cost of revenue, exclusive of depreciation and amortization			60,235			51,215			169,587			142,814
Operating expenses:
Research and development			4,018			3,699			11,226			11,069
Sales and marketing			2,857			2,719			7,678			8,225
General and administrative			27,917			14,393			58,945			45,725
Long-lived asset impairment charge			—			—			4,062			—
Depreciation and amortization			5,723			5,328			16,954			15,109
Total operating expenses			40,515			26,139			98,865			80,128
Loss from operations			(23,649)			(9,444)			(51,644)			(31,957)
Other income (expense):
Interest expense, net			(2,717)			(2,230)			(7,430)			(6,959)
Other income			479			—			479			—
Total other expense, net			(2,238)			(2,230)			(6,951)			(6,959)
Loss from continuing operations before income taxes			(25,887)			(11,674)			(58,595)			(38,916)
Income tax (benefit) expense			(7)			82			368			284
Net loss from continuing operations			(25,880)			(11,756)			(58,963)			(39,200)
Net loss from discontinued operations, net of tax			(14,185)			(5,355)			(58,905)			(18,484)
Net loss		$	(40,065)		$	(17,111)		$	(117,868)		$	(57,684)
Net loss per share:
Net loss per share from continuing operations, basic and diluted		$	(1.07)		$	(0.50)		$	(2.45)		$	(1.68)
Net loss per share from discontinued operations, basic and diluted			(0.58)			(0.23)			(2.45)			(0.80)
Total net loss per share, basic and diluted		$	(1.65)		$	(0.73)		$	(4.90)		$	(2.48)
Weighted average common shares outstanding, basic and diluted			24,350,182			23,407,391			24,075,666			23,230,138

 

TABULA RASA HEALTHCARE, INC. UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)
		Nine Months Ended
		September 30,
		2022			2021
Cash flows from operating activities:
Net loss		$	(117,868)		$	(57,684)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization			24,285			35,343
Amortization of deferred financing costs and debt discount			1,972			1,714
Deferred taxes			(513)			337
Stock-based compensation			32,537			28,962
Acquisition-related contingent consideration paid			—			(67)
Impairment charges			46,355			—
Loss on divestiture of business			2,879			—
Other noncash items			(9)			9
Changes in operating assets and liabilities, net of effect of divestiture:
Accounts receivable, net			5,107			789
Inventories			(291)			(866)
Prepaid expenses and other current assets			(1,375)			(6,084)
Client claims receivables			(4,936)			(872)
Other assets			(1,357)			(2,604)
Accounts payable			5,074			1,587
Accrued expenses and other liabilities			13,534			2,138
Client claims payables			1,139			423
Other long-term liabilities			3,220			(108)
Net cash provided by operating activities			9,753			3,017
Cash flows from investing activities:
Purchases of property and equipment			(1,021)			(1,611)
Software development costs			(23,860)			(22,649)
Proceeds from divestiture of business			118,561			—
Net cash provided by (used in) investing activities			93,680			(24,260)
Cash flows from financing activities:
Proceeds from exercise of stock options			64			3,683
Payments for employee taxes for shares withheld			(1,112)			—
Payments for debt financing costs			(350)			(8)
Borrowings on line of credit			27,700			17,500
Repayments of line of credit			(57,200)			—
Payment of acquisition-related notes payable			—			(13,000)
Payments of acquisition-related contingent consideration			—			(99)
Repayments of long-term debt and finance leases			—			(4)
Net cash (used in) provided by financing activities			(30,898)			8,072
Net increase (decrease) in cash and restricted cash			72,535			(13,171)
Cash and restricted cash, beginning of period			15,706			28,532
Cash and restricted cash, end of period		$	88,241		$	15,361

 

TABULA RASA HEALTHCARE, INC. UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP MEASURES (In thousands)
		Three Months Ended September 30,						Nine Months Ended September 30,
		2022			2021			2022			2021
Reconciliation of Net Loss to Adjusted EBITDA from Continuing Operations
Net loss		$	(40,065)		$	(17,111)		$	(117,868)		$	(57,684)
Add:
Interest expense, net			2,717			2,230			7,430			6,959
Income tax (benefit) expense			(7)			82			368			284
Depreciation and amortization			5,723			5,328			16,954			15,109
Impairment charges			—			—			4,062			—
Business optimization expenses			—			—			787			—
Severance costs			122			354			697			516
Executive transition			1,821			—			1,971			—
Cooperation agreement costs			1,122			—			1,122			—
Divestiture-related expense			1,057			—			2,591			—
Acquisition-related expense			—			—			—			217
Stock-based compensation expense			15,378			6,901			28,173			24,100
Loss from discontinued operations			14,185			5,355			58,905			18,484
Adjusted EBITDA from continuing operations		$	2,053		$	3,139		$	5,192		$	7,985
Adjusted EBITDA (loss) from discontinued operations			(3,593)			2,578			(1,036)			7,294
Total Adjusted EBITDA (loss)		$	(1,540)		$	5,717		$	4,156		$	15,279
		Three Months Ended September 30,						Nine Months Ended September 30,
		2022			2021			2022			2021
Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA (Loss) from Discontinued Operations
Net loss from discontinued operations, net of tax		$	(14,185)		$	(5,355)		$	(58,905)		$	(18,484)
Add:
Income tax (benefit) expense			(94)			52			(662)			182
Depreciation and amortization			—			6,771			7,331			20,234
Impairment charges			5,845			—			42,293			—
Loss on disposal of business			2,879			—			2,879			—
Settlement			—			—			1,448			500
Divestiture-related expense			104			—			216			—
Stock-based compensation expense			1,858			1,110			4,364			4,862
Adjusted EBITDA (loss) from discontinued operations		$	(3,593)		$	2,578		$	(1,036)		$	7,294

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tabula-rasa-healthcare-reports-third-quarter-2022-results-301668186.html

SOURCE Tabula Rasa HealthCare, Inc.

FAQ

What were Tabula Rasa HealthCare's Q3 2022 revenue figures?

Tabula Rasa HealthCare reported Q3 2022 revenue of $77.1 million, a 14% increase from $67.9 million in the same quarter last year.

How did the GAAP net loss of TRHC change in Q3 2022?

TRHC's GAAP net loss from continuing operations increased to $25.9 million in Q3 2022, compared to a loss of $11.8 million in Q3 2021.

What is the current cash position of Tabula Rasa HealthCare?

As of September 30, 2022, Tabula Rasa HealthCare reported cash of $80.8 million, significantly up from $26.5 million as of June 30, 2022.

Did TRHC experience growth in PACE participants in Q3 2022?

Yes, TRHC saw an 8% increase in PACE participants, totaling 52,230 by September 30, 2022.

What is the outlook for TRHC's revenue growth in Q4 2022?

TRHC's guidance for Q4 2022 indicates total revenue from continuing operations is expected to range from $77.5 million to $80.5 million, reflecting a year-over-year growth of 12% to 17%.